"Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate"@en . "Moracizin"@en . "Humans and other mammals"@en . . . . "Ethmozin"@en . "Moracizine"@en . "Well absorbed, absorption is complete within 2 to 3 hours. Significant first-pass metabolism results in an absolute bioavailability of approximately 38%. Administration within 30 minutes after a meal slows the rate, but does not affect the extent of absorption, although peak plasma concentrations are reduced."@en . . . "31883-05-3"@en . . "Symptoms of overdose include vomiting, unconsciousness, and severe low blood pressure."@en . . . . . . . . . "EN-313"@en . " "@en . "approved"@en . . "Approximately 95%."@en . . "Etmozin"@en . . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Moricizine.htm"@en . . . "Moricizine works by inhibiting the rapid inward sodium current across myocardial cell membranes."@en . "Less than 1% of orally administered Ethmozine\u00AE is excreted unchanged in the urine. Approximately 56% of the administered dose is excreted in the feces and 39% is excreted in the urine."@en . . . . . . . "Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate"@en . " "@en . . "An antiarrhythmia agent used primarily for ventricular rhythm disturbances. [PubChem]"@en . . . . . . . . "Moricizine"@en . "* 300 L"@en . . . "2 hours (range 1.5-3.5 hours)."@en . "withdrawn"@en . . . . . . . "Moricizine"@en . . "[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester"@en . "Moracizinum"@en . . "Used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate."@en . . "Moracizina"@en .